Company profile: Megazyme
1.1 - Company Overview
Company description
- Provider of analytical enzymes, chromogenic substrates, high-purity polysaccharides and colourimetric oligosaccharides; assay kits including Rapid Integrated Total Dietary Fiber and Lactose Assay; and Food Safety Division dehydrated culture media and diagnostic tests for foodborne bacteria, natural toxins, genetic modifications and allergens, serving laboratories in food & beverages, biofuel, animal feed, wine & brewing, dairy and cereals.
Products and services
- Chromogenic Substrates: Assay-grade Chromogenic Substrates are used for the assay of hydrolytic enzymes, delivering insights into enzyme mechanisms and activities for characterizing specific hydrolytic reactions
- Enzymes: Analytical-grade Enzymes with high purity support analytical, diagnostic, and research applications across industries including food, brewing, and biofuels
- Rapid Integrated Total Dietary Fiber Kit: Laboratory-grade Rapid Integrated Total Dietary Fiber Kit is designed for accurate measurement of dietary fiber, particularly resistant starch components, in controlled laboratory analysis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Megazyme
GenArraytion
HQ: United States
Website
- Description: Provider of medical diagnostics products and services for tick- and mosquito-borne disease and surveillance, epidemiology and source tracking, food and water testing, biodefense and environmental monitoring, including MultiFLEX Bioassays and Sniper Sequencing genotyping services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenArraytion company profile →
Codexis
HQ: United States
Website
- Description: Provider of enzyme discovery and RNA manufacturing solutions, offering the CodeEvolver platform to discover, develop, and enhance novel enzymes and proteins; ECO Synthesis technology for scaled enzymatic production of RNAi therapeutics; custom enzymes to improve small molecule pharmaceutical manufacturing; RNA ligase screening and optimization; and high-yield RNA manufacturing services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Codexis company profile →
Chromatin
HQ: United States
Website
- Description: Provider of plant breeding and genomics technologies for agricultural, energy, chemical, nutritional and pharmaceutical sectors. Develops sorghum for agriculture and renewable energy, and advances maize and wheat via high-yielding, disease- and climate-resilient traits. Services include genomic selection, high-throughput phenotyping, multi-trait analysis, environics for genotype prediction, and integrated genomics-phenomics modeling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chromatin company profile →
AnimalBiome
HQ: United States
Website
- Description: Provider of microbiome-focused pet health solutions for dogs and cats, including gut health test kits for stool-based microbiome analysis, gut restore supplements with healthy bacteria, gut maintenance products with prebiotics and probiotics, oral health products with prebiotic action, a State of the Gut report with dietary and exercise recommendations, and microbiome research partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AnimalBiome company profile →
XyloCor Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for coronary artery disease: XC001 treats refractory angina by stimulating new coronary blood vessel formation; XC002 is in development to regenerate cardiac tissue in heart failure after past heart attacks by converting non-functioning cardiac cells into functioning ones.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XyloCor Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Megazyme
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Megazyme
2.2 - Growth funds investing in similar companies to Megazyme
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Megazyme
4.2 - Public trading comparable groups for Megazyme
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →